Ann: September Update, page-8

Some more on the above from http://www.investing.businessweek.w...asp?personId=226982114&privcapId=35411569

Mr. Michael Johnson serves as the Chief Executive Officer and Managing Director of Rhinomed Limited (formerly, Consegna Group Limited) and has been its Executive Director since February 1, 2013. Mr. Johnson serves as a Director of Melbourne based Cogentum. His experience includes advising the team at Acrux (ASX:ACR) as they successfully licensed the Axiron® product with Eli Lilly, the largest biotech licensing deal in Australia at the time and CogState (ASX:CGS) as they effectively entered the sport concussion market. Mr. Johnson has held senior roles with some of the world's most successful marketing and communication firms where he has successfully launched a number of high profile new products and brands.

Dewhurst and US / Canadian Sub. shareholders - not in here for fun that's for sure .. cross fingers and hang on IMO